ERBB2 and cancer: As shown in Figure 7C, cancer cells (HER2-positive and F4/80-negative) and TAMs (F4/80-positive and HER2-negative) represented 56.6% ± 6.7% and 7.3% ± 1.3%, respectively, of the total tumor cells harvested from the tumors in the cohort without 2.4G2 antibody treatment, and 52.0% ± 8.6% and 9.0% ± 3.3%, respectively, of the total tumor cells harvested from the tumors in the cohort with 2.4G2 treatment.